Is Now The Time To Look At Buying Medical Data Vision Co., Ltd. (TSE:3902)?

Medical Data Vision Co., Ltd. (TSE:3902), might not be a large cap stock, but it led the TSE gainers with a relatively large price hike in the past couple of weeks. The recent rally in share prices has nudged the company in the right direction, though it still falls short of its yearly peak. Less-covered, small caps sees more of an opportunity for mispricing due to the lack of information available to the public, which can be a good thing. So, could the stock still be trading at a low price relative to its actual value? Today we will analyse the most recent data on Medical Data Vision’s outlook and valuation to see if the opportunity still exists.

View our latest analysis for Medical Data Vision

What's The Opportunity In Medical Data Vision?

According to our valuation model, Medical Data Vision seems to be fairly priced at around 8.6% below our intrinsic value, which means if you buy Medical Data Vision today, you’d be paying a fair price for it. And if you believe the company’s true value is ¥613.00, then there’s not much of an upside to gain from mispricing. What's more, Medical Data Vision’s share price may be more stable over time (relative to the market), as indicated by its low beta.

Can we expect growth from Medical Data Vision?

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Medical Data Vision's earnings over the next few years are expected to double, indicating a very optimistic future ahead. This should lead to stronger cash flows, feeding into a higher share value.

What This Means For You

Are you a shareholder? It seems like the market has already priced in 3902’s positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value?

Are you a potential investor? If you’ve been keeping an eye on 3902, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. While conducting our analysis, we found that Medical Data Vision has 3 warning signs and it would be unwise to ignore them.

If you are no longer interested in Medical Data Vision, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.